Detection and clinical importance of minimal residual disease in patients with lung cancer - a pilot study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F11%3A10224852" target="_blank" >RIV/61989592:15110/11:10224852 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Detection and clinical importance of minimal residual disease in patients with lung cancer - a pilot study

Popis výsledku v původním jazyce

Lung cancer is one of the leading causes of cancer death and has become an increasingly urgent worldwide health problem (incidence in men 34.01100 000, in women 13.61100 000; mortality in men 29.3/100 000, in women 11.0/1 00 000) (globocan.iarc. fr, 2008). Mortality is increasingly associated with distant metastases development. The minimal residual disease (MRD) in solid tumours means the presence of occult tumour cells in the body of a patient who has undergone curative surgery and has no timher clinical signs of the disease. These isolated occult tumour cells are considered to be the precursors of micrometastases. The MRD testing in lung cancer patients can eliminate complicated surgical procedures in patients with systemic molecular dissemination of the disease and can improve the prognosis. The aim of our pilot study was to establish and validate PCR-based method for MRD testing in lung cancer using different molecular markers.

Název v anglickém jazyce

Detection and clinical importance of minimal residual disease in patients with lung cancer - a pilot study

Popis výsledku anglicky

Lung cancer is one of the leading causes of cancer death and has become an increasingly urgent worldwide health problem (incidence in men 34.01100 000, in women 13.61100 000; mortality in men 29.3/100 000, in women 11.0/1 00 000) (globocan.iarc. fr, 2008). Mortality is increasingly associated with distant metastases development. The minimal residual disease (MRD) in solid tumours means the presence of occult tumour cells in the body of a patient who has undergone curative surgery and has no timher clinical signs of the disease. These isolated occult tumour cells are considered to be the precursors of micrometastases. The MRD testing in lung cancer patients can eliminate complicated surgical procedures in patients with systemic molecular dissemination of the disease and can improve the prognosis. The aim of our pilot study was to establish and validate PCR-based method for MRD testing in lung cancer using different molecular markers.

Druh

D - Stať ve sborníku

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název statě ve sborníku

New Frontiers in the Research of PhD Students. Conference of Medical Schools.

ISBN

978-80-260-0922-1

ISSN

—

e-ISSN

—

Počet stran výsledku

4

Strana od-do

12-15

Název nakladatele

Univerzita Karlova

Místo vydání

Praha

Místo konání akce

Hradec Králové

Datum konání akce

10. 11. 2011

Typ akce podle státní příslušnosti

EUR - Evropská akce

Kód UT WoS článku

—